The Role of ACE Inhibitors in Slowing Diabetic Nephropathy Progression: A Comprehensive Review

Abstract

Diabetic nephropathy (DN), a significant microvascular complication of diabetes mellitus, is a major cause of end-stage renal disease globally. Chronic hyperglycemia, renin-angiotensin-aldosterone system (RAAS) activation, oxidative stress, and inflammation are among the metabolic and hemodynamic variables that interact intricately in the pathophysiology of diabetic nephropathy (DN), which results in progressive glomerular damage and fibrosis. Because of their capacity to alter RAAS activity, lower intraglomerular pressure, and lessen structural kidney damage, angiotensin-converting enzyme (ACE) inhibitors have become a mainstay in the treatment of diabetic kidney disease (DN). ACE inhibitors have renoprotective benefits in addition to lowering blood pressure because they reduce proteinuria, mitigate mesangial expansion, and restrict the buildup of extracellular matrix. This review summaries data from observational studies, clinical trials, and meta-analyses assessing the safety and effectiveness of ACE inhibitors in delaying the progression of DN. Large randomized trials have repeatedly shown that patients on ACE inhibitors, especially in the early stages of DN, have lower albuminuria and a delayed start of end-stage renal disease. Alongside suggested monitoring, safety factors such as hyperkalaemia, coughing, and acute renal injury are covered. With specific blood pressure objectives and initiation criteria, ACE inhibitors are strongly recommended as first-line therapy in DN by current clinical guidelines. This review demonstrates the critical role that ACE inhibitors play in the treatment of DN by combining pathophysiological insights, mechanistic data, and clinical evidence. Even with their proven advantages, more research is necessary to improve therapy, investigate combination regimens, and tailor treatment plans according to phenotypic and genetic characteristics.

Keywords

Introduction

ACE medications produce notable hemodynamic effects that directly oppose these harmful processes by blocking the production of angiotensin II. They cause vasodilation, which lowers intraglomerular pressure and, more importantly, systemic blood pressure. A substantial decrease in proteinuria and albuminuria results from this decrease in intraglomerular pressure, which is essential for reducing the leaking of proteins into the urine. By reducing the mechanical stress on the fragile glomerular filtration barrier, this pressure normalization maintains kidney function [17]. In addition to their hemodynamic effects, ACE inhibitors have important non-hemodynamic effects that support their benefits for protecting the kidneys. Since ACE inhibitors block angiotensin II, which promotes inflammation and fibrosis, these degenerative processes within the kidney are successfully mitigated. Additionally, ACE drugs and other RAAS inhibitors have immunomodulatory qualities. In diabetic nephropathy models, for example, enalapril, a particular ACE inhibitor, has been demonstrated to enhance T cell counts and encourage local polarization towards M1-like macrophages within the kidney, indicating the potential to alter the inflammatory milieu that fuels the development of DN. These combined hemodynamic and non-hemodynamic effects highlight the effectiveness of ACE inhibitors in maintaining kidney function over time and reducing the progression of diabetic nephropathy [17,18].

4 Clinical Evidence

An extensive body of clinical evidence, including large randomized trials, thorough meta-analyses, and observational studies, supports the idea that angiotensin-converting enzyme (ACE) inhibitors can reduce the course of diabetic nephropathy (DN). These studies repeatedly show that ACE inhibitors are effective in preventing renal damage, lowering proteinuria, and maintaining kidney function in diabetic patients. The continuous efforts to convert innovative treatments for diabetic kidney disease from evidence to broad clinical use highlight their importance [19].

4.1 Major Randomized Trials

The combined body of evidence from these trials, as compiled in numerous reviews and meta-analyses, forms the foundation of current clinical practice regarding ACE inhibitors in DN, even though the sources cited do not specifically describe large-scale, named randomized controlled trials with their precise population sizes and direct outcomes [17,18]. A common first-line treatment for hypertensive people with diabetic nephropathy is an ACE inhibitor. Patients with diabetes are also frequently prescribed them, occasionally in combination with angiotensin II receptor blockers (ARBs). It has been repeatedly demonstrated that ACE inhibitor treatment, both short-term and long-term, can stop the progression of diabetic nephropathy. The decrease in albuminuria is one of the main results that shows how effective they are. The clinical trials demonstrate that RAS inhibition, which is accomplished by medications like as ACE inhibitors, is still a key component of DN treatment [20].

4.2 Meta-Analyses

By integrating information from several research, meta-analyses offer solid proof and a thorough understanding of treatment efficacy:

1. Both calcium channel blockers (CCBs) and ACE inhibitors are helpful in preventing the progression of diabetic nephropathy, according to a meta-analysis comparing their short- and long-term use. If direct comparisons of the amount of effect are available, this meta-analysis would require more examination. The prevention of the progression of DN was the specific focus of this meta-analysis [12].
2. The wider efficacy of first-line medications that block the renin-angiotensin system (RAS) in comparison to other first-line antihypertensive medication classes for hypertension is revealed by a Cochrane review. This review aids in placing the overall effectiveness of RAS inhibitors in context, despite its broad focus on hypertension [15].
3. The impact of supplementing ACE inhibitors or angiotensin receptor blockers (ARBs) with Tripterygium glycosides on albuminuria in individuals with diabetic nephropathy was investigated in another meta-analysis. This emphasizes the crucial role that ACE inhibitors play as a foundational treatment to which additional drugs may be added [20].
4. Together, these meta-analyses support the idea that ACE inhibitors can help diabetic patients avoid negative renal outcomes, mainly by lowering albuminuria and delaying the course of the disease [19].

4.3 Observational Studies

The comparative profiles and practical efficacy of ACE inhibitors in the treatment of DN are further supported by observational studies:

1. Both kinds of medications are helpful in diabetic nephropathy, according to a retrospective study that looked at the effects of ACE inhibitors and ARBs. The two primary classes of RAS inhibitors are directly compared in this study, showing comparable beneficial effects in lowering microalbuminuria. This implies that their eventual clinical benefit in DN is similar, despite minor differences in their processes [21].
2. In Northwestern Ethiopia, comparative retrospective cohort research examined the renal outcomes of diabetic patients receiving ACE inhibitors in addition to calcium channel blockers or thiazide diuretics. The study design itself depicts a real-world situation where ACE inhibitors are a crucial part of combination therapy, even though it does not specify particular results [23].
3. Another study evaluated how ACE inhibitors and ARBs are currently used in diabetic hypertensive and non-hypertensive patients. This study demonstrated their extensive use, pointing to their established function in clinical practice for both patient groups and subtly recognizing their alleged advantages in practical contexts [23].

In conclusion, the clinical data continuously shows how important ACE inhibitors are for the treatment of diabetic nephropathy. Because of their proven ability to lower albuminuria, regulate blood pressure, and directly maintain kidney function, ACE inhibitors continue to be a vital and essential part of treatment plans meant to delay the course of DN.

5 Safety and Adverse Effects

The references offered mostly concentrate on the clinical effectiveness and mode of action of angiotensin-converting enzyme (ACE) inhibitors in the treatment of diabetic nephropathy (DN), emphasizing their vital importance as a therapeutic approach. Although the sources go into great detail about how ACE inhibitors can reduce intraglomerular pressure, prevent fibrosis, and modulate the renin-angiotensin-aldosterone system (RAS), they don't go into detail about common side effects like coughing, hypotension, hyperkalaemia, or clear changes in renal function [22]. Similarly, the extracts presented do not specifically address the contraindications for the use of ACE inhibitors in individuals with diabetic nephropathy.  The clinical data from the sources above consistently places ACE inhibitors as a basic and first-line treatment for diabetic nephropathy, even in the absence of specific information on side effects or contraindications. It has been repeatedly demonstrated that both short-term and long-term ACE inhibitor treatment can significantly lower albuminuria and stop the progression of diabetic nephropathy [21]. An overall favourable risk-benefit profile for their specified applications is implied by their extensive usage and strong recommendation in contemporary clinical practice for hypertensive patients with diabetic nephropathy, as well as frequently for non-hypertensive diabetic patients [17]. Their proven importance in maintaining kidney function over time is further supported by the literature's emphasis on the beneficial renal outcomes, such as decreased microalbuminuria.
However, it is impossible to formulate a detailed discussion of these safety aspects or the nuanced risk-benefit balance in individual diabetic nephropathy patients based solely on the provided material without specific data from the references provided regarding the incidence or management of adverse effects, or explicit contraindications. The sources continue to highlight the therapeutic benefits and critical function of ACE inhibitors in reducing the rate at which renal damage develops in diabetic individuals [19,20].

6 Current Clinical Guidelines

The sources cited consistently emphasize the critical and well-established role of angiotensin-converting enzyme (ACE) inhibitors in the treatment of diabetic nephropathy (DN), even though they do not specifically outline specific clinical guidelines from organizations like KDIGO or ADA with their exact blood pressure (BP) targets or thorough initiation and avoidance criteria. Major suggestions are reflected in the literature, which focuses on the compelling evidence for their usage and integration into contemporary therapeutic practice [21]. A common first-line treatment for hypertensive people with diabetic nephropathy is an ACE inhibitor. This positioning suggests that because of their demonstrated advantages, current clinical guidance advises their commencement in this patient category. Additionally, diabetic patients are frequently taken ACE inhibitors, occasionally in combination with angiotensin II receptor blockers (ARBs). This implies a wide range of applications, not just hypertensive patients with obvious nephropathy, because their renoprotective benefits go beyond lowering blood pressure. Both short-term and long-term treatments have consistently shown that they are effective in slowing the course of diabetic nephropathy [5-7]. The notable decrease in albuminuria seen with ACE inhibitor treatment is a major finding bolstering these recommendations. The continuous efforts to transition from evidence to the broad application of innovative treatments for diabetic kidney disease are aided by this solid body of evidence. According to the sources' combined view, RAS blockade—achieved with medications like ACE inhibitors—remains a key component of DN treatment. This is in line with clinical practice, which holds that ACE inhibitors are essential for preventing kidney damage in diabetics. The constant advice for ACE inhibitors in patients with hypertensive diabetic nephropathy implicitly corresponds with the goal of optimal blood pressure control to protect kidney function, even though exact numerical blood pressure targets are not specified in these passages [9-11]. In conclusion, despite the lack of explicit references to KDIGO or ADA guidelines, the evidence presented clearly favors the use of ACE inhibitors as a first-line treatment for diabetic nephropathy, particularly in hypertensive patients, because of their demonstrated capacity to lower albuminuria and slow the progression of the disease. These agents' extensive use in clinical practice reinforces their function in upholding the best available evidence for patient care. The articles cited don't go into great detail about specific contraindications or specific situations to avoid.

7 Future Directions & Research Gaps

Even though angiotensin-converting enzyme (ACE) inhibitors are known to be effective in treating diabetic nephropathy (DN), there are still a number of areas that need more research to maximize treatment results and fill in knowledge gaps. The shift from proven evidence to the broad application of innovative treatments for diabetic kidney disease is a major obstacle. This points to the urgent need for studies concentrating on practical methods for more widely and effectively incorporating currently approved therapies, including ACE inhibitors, into standard clinical practice [23]. Beyond the conventional focus on ACE inhibition, more study is essential to investigate new molecular mechanisms and alternate pathways within the intrarenal renin-angiotensin system, as these could provide new therapeutic targets. One intriguing option for investigating non-traditional drugs that protect against tubulopathy is the study of Farnesoid X Receptor (FXR) agonism, which suggests a possible add-on therapy for diabetic nephropathy. Similarly, an intriguing and significant topic for future therapeutic research is the possibility of new peptides such as Angiotensin-(1–7) as therapies for hypertension and nephropathy in diabetes [14-16]. The optimization of combination medicines is another important research need. To further improve renal protection, the best supplemental therapies must be developed, even though ACE inhibitors constitute the cornerstone. This requirement for synergistic methods is shown by studies examining the advantages of combining substances such tripterygium glycosides with ACE inhibitors or ARBs to improve albuminuria [18]. Additionally, research on vitamin D's possible use as an adjuvant medication in diabetic patients in addition to ACE inhibitors and ARBs may yield important information about comprehensive treatment plans. Therapeutic methods are also improved by comparative studies on different combination regimens, such as ACE inhibitors with calcium channel blockers or thiazide diuretics [9-11]. Lastly, for individualized therapy, it is still essential to comprehend the variability of patient response. To move closer to personalized medical methods, it is essential to investigate how Angiotensin-Converting Enzyme (ACE) polymorphisms affect the likelihood of developing diabetic nephropathy and how well it responds to treatment. Different treatment outcomes may be explained by this genetic heterogeneity, which may also help guide future customized therapy approaches. Beyond their main functions in heart failure and hypertension, further clarification of the immunomodulatory effects of RAAS inhibitors offers an intriguing field for future research that may lead to the discovery of more extensive therapeutic uses [22,23].

8 CONCLUSIONS

Unquestionably, an essential and first-line treatment approach for diabetic nephropathy (DN) is the use of angiotensin-converting enzyme (ACE) inhibitors. Their critical function in reducing the progression of renal damage in diabetic patients is continuously demonstrated by the extensive evidence presented. Their shown capacity to significantly lower albuminuria, a crucial indicator and predictor of the progression of DN, is a major clinical advantage that has been emphasized time and time again. Their influence on the renin-angiotensin-aldosterone system (RAS), which helps to regulate intraglomerular pressure and lessen fibrosis, is what gives them this renoprotective effect. The value of ACE inhibitors in contemporary therapeutic practice has been established by their consistent ability to stop the progression of DN in both short-term and long-term treatment. A favorable risk-benefit profile for their recommended applications is implied by their widespread recommendation for hypertensive patients with diabetic nephropathy and frequently for non-hypertensive diabetics. The current therapeutic significance of ACE inhibitors as the cornerstone of RAS blocking in DN remains crucial, even though the sources also suggest future paths in understanding genetic response variants, optimizing combination treatments, and investigating novel molecular processes. All things considered, ACE inhibitors are essential resources for maintaining kidney function and enhancing the prognosis of patients with diabetic nephropathy.

REFERENCES

1. Dwivedi S, Sikarwar MS. Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies. Horm Metab Res. 2025 Jan;57(1):7-17. doi: 10.1055/a-2435-8264.
2. Tuttle KR, Wong L, St Peter W, Roberts G, Rangaswami J, Mottl A, Kliger AS, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC 3rd, Argyropoulos C, Quaggin SE; Diabetic Kidney Disease Collaborative Task Force. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2022 Jul;17(7):1092-1103. doi: 10.2215/CJN.02980322.
3. Sawaf H, Thomas G, Taliercio JJ, Nakhoul G, Vachharajani TJ, Mehdi A. Therapeutic Advances in Diabetic Nephropathy. J Clin Med. 2022 Jan 13;11(2):378. doi: 10.3390/jcm11020378.
4. Canadian Agency for Drugs and Technologies in Health. Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jun 12 [cited 2024 Oct 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/26180887/
5. Heyman SN, Raz I, Dwyer JP, Weinberg Sibony R, Lewis JB, Abassi Z. Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. Cells. 2022 Sep 18;11(18):2917. doi: 10.3390/cells11182917.
6. Król-Kulikowska M, Abramenko N, Jakubek M, Banasik M, Kepinska M. The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy. J Clin Med. 2024 Feb 8;13(4):995. doi: 10.3390/jcm13040995.
7. Graves LE, Donaghue KC. Management of diabetes complications in youth. Ther Adv Endocrinol Metab. 2019 Jul 25; 10:2042018819863226. doi: 10.1177/2042018819863226.
8. Liang J, Lan J, Tang Q, Ling W, Li M. Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis. Exp Ther Med. 2021 Jan;21(1):14. doi: 10.3892/etm.2020.9446.
9. Bahreini E, Rezaei-Chianeh Y, Nabi-Afjadi M. Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review. Rev Diabet Stud. 2021 Spring;17(1):1-10. doi: 10.1900/RDS.2021.17.1.
10. Pathak JV, Dass EE. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Indian J Pharmacol. 2015 Mar-Apr;47(2):148-52. doi: 10.4103/0253-7613.153420.
11. Lozano-Maneiro L, Puente-García A. Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. J Clin Med. 2015 Nov 9;4(11):1908-37. doi: 10.3390/jcm4111908.
12. Eriguchi M, Lin M, Yamashita M, Zhao TV, Khan Z, Bernstein EA, Gurley SB, Gonzalez-Villalobos RA, Bernstein KE, Giani JF. Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy. Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F531-F542. doi: 10.1152/ajprenal.00523.2017.
13. Netere AK, Muhammad EA, Asres MS, Teklie MT. Renal outcomes of diabetic patients treated with combination therapy of ACE inhibitors plus either thiazide diuretics or calcium channel blockers: comparative retrospective cohort study in Northwestern Ethiopia. BMJ Open. 2021 Nov 25;11(11):e048442. doi: 10.1136/bmjopen-2020-048442.
14. Wang H, Karnati S, Madhusudhan T. Regulation of the Homeostatic Unfolded Protein Response in Diabetic Nephropathy. Pharmaceuticals (Basel). 2022 Mar 25;15(4):401. doi: 10.3390/ph15040401.
15. Sukkarieh HH, Bustami RT, Abdu MN, Khokhar AA, Salih AA, Abdalla HK. The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Saudi Med J. 2020 Oct;41(10):1083-1089. doi: 10.15537/smj.2020.10.25428.
16. Cucak H, Nielsen Fink L, Højgaard Pedersen M, Rosendahl A. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy. Int Immunopharmacol. 2015 Mar;25(1):30-42. doi: 10.1016/j.intimp.2015.01.003.
17. Fang JY, Yang Y, Zhang Z, Jiang SM, Yu TY, Li WG. Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy. Chronic Dis Transl Med. 2020 Feb 10;6(1):18-26. doi: 10.1016/j.cdtm.2019.12.008.
18. Modafferi S, Ries M, Calabrese V, Schmitt CP, Nawroth P, Kopf S, Peters V. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther. 2019 Feb;10(1):229-243. doi: 10.1007/s13300-018-0551-9.
19. Sanglard A, Miranda BCB, Vieira ALF, Macedo MVM, Santos RL, Campos ASRR, Piva AC, Simoes E Silva AC. The Role of Renin-Angiotensin System in Diabetic Nephropathy: An Update. Mini Rev Med Chem. 2025;25(8):591-600. doi: 10.2174/0113895575344980250130062547.
20. Haliga RE, Cojocaru E, Sîrbu O, Hri?cu I, Alexa RE, Haliga IB, ?orodoc V, Coman AE. Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure. Biomedicines. 2025 Jul 21;13(7):1779. doi: 10.3390/biomedicines13071779.
21. Marquardt A, Al-Dabet MM, Ghosh S, Kohli S, Manoharan J, ElWakiel A, Gadi I, Bock F, Nazir S, Wang H, Lindquist JA, Nawroth PP, Madhusudhan T, Mertens PR, Shahzad K, Isermann B. Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy. J Am Soc Nephrol. 2017 Nov;28(11):3182-3189. doi: 10.1681/ASN.2016101123.
22. Padda RS, Shi Y, Lo CS, Zhang SL, Chan JS. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes? J Diabetes Metab. 2015 Oct 14;6(10):10.4172/2155-6156.1000615. doi: 10.4172/2155-6156.1000615.
23. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2.